Expression and methylation status of BTG2, PPP1CA, and PEG3 genes in colon adenocarcinoma cell lines: promising treatment targets

Aim: This study investigated the association between methylation status and expression levels of BTG2, PPP1CA, and PEG3 genes in colon cancer. Background: Aberrant DNA methylation is one of the most important epigenetic modifications in the development of cancer. Evidence indicates that hypermethylation of various tumor suppressor genes could be a potential mechanism of colon tumorigenesis. Methods: The expression levels of BTG2, PPP1CA, and PEG3 genes were evaluated in HT-29/219, HCT116, SW48, SW742, SW480, and LS180 cell lines using quantitative Real-Time PCR. The methylation status of BTG2 and PPP1CA was determined by methylation-specific PCR (MSP) method, and the methylation pattern of PEG3 was evaluated by bisulfite sequencing PCR (BSP). To investigate the effect of methylation on the expression of these genes, all colon cancer cell lines were treated by 5-Azacitidine (5-Aza) and/or Trichostatin A (TSA). Results: The expression levels of BTG2, PPP1CA, and PEG3 were highly heterogeneous and quantitatively correlated to their promoter methylation status in the studied colon cancer cell lines. Treatment by 5-Aza and/or TSA increased the expression of the above-named genes in colon cancer cell lines. Conclusion: Overall, it seems that BTG2, PPP1CA, and PEG3 act as tumor suppressor genes in colon cancer, and methylation is a potential mechanism for their loss of expression. Therefore, these genes may be considered as suitable targets for demethylation approaches and, eventually, colon cancer treatment. Combined treatment by 5-Aza and TSA may be a promising therapeutic strategy for colon cancer treatment. Further studies may contribute to confirm these results.

[1]  Chunxiao Sun,et al.  Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms. , 2021, Mutation research. Reviews in mutation research.

[2]  H. Ashktorab,et al.  Altered ARID1A expression in colorectal cancer , 2020, BMC Cancer.

[3]  R. Schneider-Stock,et al.  DNA methylation and chromatin modifiers in colorectal cancer. , 2019, Molecular aspects of medicine.

[4]  G. Lippi,et al.  Concise update on colorectal cancer epidemiology. , 2019, Annals of translational medicine.

[5]  A. Farhadi,et al.  The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR‐125b, miR‐17, and miR‐181b in NALM6 cell line , 2019, Journal of cellular biochemistry.

[6]  Cui Tang,et al.  The role of PEG3 in the occurrence and prognosis of colon cancer , 2019, OncoTargets and therapy.

[7]  Mozhdeh Zamani,et al.  Relationship between Arg753Gln Toll-like receptor 2 and Asp299Gly Toll-like receptor 4 genetic variations and susceptibility to colorectal cancer in southern Iran , 2018 .

[8]  M. Esteller,et al.  A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer , 2018, Molecular oncology.

[9]  P. Mokarram,et al.  Epigenetic biomarkers in colorectal cancer: premises and prospects , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  Xiao‐Yu Yin,et al.  BTG2 Is Down-Regulated and Inhibits Cancer Stem Cell-Like Features of Side Population Cells in Hepatocellular Carcinoma , 2017, Digestive Diseases and Sciences.

[11]  W. Yin,et al.  Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells , 2017, OncoTargets and Therapy.

[12]  Michael D. Wilson,et al.  Epigenetics of Atherosclerosis: Emerging Mechanisms and Methods. , 2017, Trends in molecular medicine.

[13]  Peter A. Jones,et al.  Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[14]  Jianwen Liu,et al.  MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2 , 2016, Oncotarget.

[15]  F. Charchar,et al.  Epigenetic Modifications in Essential Hypertension , 2016, International journal of molecular sciences.

[16]  N. Han,et al.  Time course analysis based on gene expression profile and identification of target molecules for colorectal cancer , 2016, Cancer Cell International.

[17]  M. Mahmoudi,et al.  Epigenetic alterations underlying autoimmune diseases , 2016, Autoimmunity.

[18]  William M. Grady,et al.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. , 2015, Gastroenterology.

[19]  C. Klinge,et al.  5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. , 2014, Cancer letters.

[20]  C. Cinti,et al.  Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line , 2014, PloS one.

[21]  Hana Kim,et al.  Peg3 Mutational Effects on Reproduction and Placenta-Specific Gene Families , 2013, PloS one.

[22]  G. Muto,et al.  BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition , 2013, Oncogene.

[23]  J. Li,et al.  BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells , 2013, Tumor Biology.

[24]  P. Mokarram,et al.  Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer , 2012, Molecular Biology Reports.

[25]  M. McCarthy,et al.  The Genetic and Epigenetic Basis of Type 2 Diabetes and Obesity , 2012, Clinical pharmacology and therapeutics.

[26]  G. Rosner,et al.  Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy , 2011, Cancer.

[27]  Junming Yue,et al.  MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma Cells* , 2011, The Journal of Biological Chemistry.

[28]  J. Ordovás,et al.  Epigenetics and cardiovascular disease , 2010, Nature Reviews Cardiology.

[29]  Benyan Wu,et al.  Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro , 2010, Molecular Biology Reports.

[30]  Min Liu,et al.  Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma , 2009, Cell Research.

[31]  Zhen Lu,et al.  Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation , 2008, Cancer.

[32]  J. Leal,et al.  PPP1CA contributes to the senescence program induced by oncogenic Ras. , 2007, Carcinogenesis.

[33]  M. Szyf,et al.  Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. , 2007, Biochemical pharmacology.

[34]  David I. Smith,et al.  Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. , 2005, Gynecologic oncology.

[35]  M. Wilcox,et al.  Genetics and Epigenetics in Major Psychiatric Disorders , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[36]  Holger Moch,et al.  Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma , 2004, Cancer Research.

[37]  H. Yoshioka,et al.  Epigenetic silencing of PEG3 gene expression in human glioma cell lines * , 2001, Molecular carcinogenesis.

[38]  A. Nairn,et al.  Regulation of protein phosphatase-1. , 2000, Chemistry & biology.